432 related articles for article (PubMed ID: 38418707)
21. Endocrine side effects induced by immune checkpoint inhibitors.
Corsello SM; Barnabei A; Marchetti P; De Vecchis L; Salvatori R; Torino F
J Clin Endocrinol Metab; 2013 Apr; 98(4):1361-75. PubMed ID: 23471977
[TBL] [Abstract][Full Text] [Related]
22. Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer.
Zhang H; Dai Z; Wu W; Wang Z; Zhang N; Zhang L; Zeng WJ; Liu Z; Cheng Q
J Exp Clin Cancer Res; 2021 Jun; 40(1):184. PubMed ID: 34088360
[TBL] [Abstract][Full Text] [Related]
23. Emerging role of natural products in cancer immunotherapy.
Dong S; Guo X; Han F; He Z; Wang Y
Acta Pharm Sin B; 2022 Mar; 12(3):1163-1185. PubMed ID: 35530162
[TBL] [Abstract][Full Text] [Related]
24. Combination cancer immunotherapy and new immunomodulatory targets.
Mahoney KM; Rennert PD; Freeman GJ
Nat Rev Drug Discov; 2015 Aug; 14(8):561-84. PubMed ID: 26228759
[TBL] [Abstract][Full Text] [Related]
25. Immune checkpoints and cancer development: Therapeutic implications and future directions.
Mehdizadeh S; Bayatipoor H; Pashangzadeh S; Jafarpour R; Shojaei Z; Motallebnezhad M
Pathol Res Pract; 2021 Jul; 223():153485. PubMed ID: 34022684
[TBL] [Abstract][Full Text] [Related]
26. Mechanisms of immune-related adverse events during the treatment of cancer with immune checkpoint inhibitors.
Weinmann SC; Pisetsky DS
Rheumatology (Oxford); 2019 Dec; 58(Suppl 7):vii59-vii67. PubMed ID: 31816080
[TBL] [Abstract][Full Text] [Related]
27. Checkpoint Inhibitors: Applications for Autoimmunity.
Tocheva AS; Mor A
Curr Allergy Asthma Rep; 2017 Sep; 17(10):72. PubMed ID: 28956259
[TBL] [Abstract][Full Text] [Related]
28. Anticancer natural products targeting immune checkpoint protein network.
Chun KS; Kim DH; Raut PK; Surh YJ
Semin Cancer Biol; 2022 Nov; 86(Pt 3):1008-1032. PubMed ID: 34838956
[TBL] [Abstract][Full Text] [Related]
29. Immune checkpoint inhibitors in gynecologic cancers with lessons learned from non-gynecologic cancers.
Menderes G; Hicks C; Black JD; Schwab CL; Santin AD
Expert Opin Biol Ther; 2016 Aug; 16(8):989-1004. PubMed ID: 27070175
[TBL] [Abstract][Full Text] [Related]
30. [The use of immune checkpoint inhibitors in routine oncology].
Schardt J
Z Rheumatol; 2020 Oct; 79(8):809-817. PubMed ID: 32936368
[TBL] [Abstract][Full Text] [Related]
31. Emerging immunotherapy targets in lung cancer.
Zhu HH; Feng Y; Hu XS
Chin Med J (Engl); 2020 Oct; 133(20):2456-2465. PubMed ID: 32947361
[TBL] [Abstract][Full Text] [Related]
32. Therapeutic uses of anti-PD-1 and anti-PD-L1 antibodies.
Philips GK; Atkins M
Int Immunol; 2015 Jan; 27(1):39-46. PubMed ID: 25323844
[TBL] [Abstract][Full Text] [Related]
33. Emerging avenues in immunotherapy for the management of malignant pleural mesothelioma.
Gray SG
BMC Pulm Med; 2021 May; 21(1):148. PubMed ID: 33952230
[TBL] [Abstract][Full Text] [Related]
34. Understanding the checkpoint blockade in lung cancer immunotherapy.
Dal Bello MG; Alama A; Coco S; Vanni I; Grossi F
Drug Discov Today; 2017 Aug; 22(8):1266-1273. PubMed ID: 28600190
[TBL] [Abstract][Full Text] [Related]
35. Cancer immunotherapy by targeting immune checkpoints: mechanism of T cell dysfunction in cancer immunity and new therapeutic targets.
Tsai HF; Hsu PN
J Biomed Sci; 2017 May; 24(1):35. PubMed ID: 28545567
[TBL] [Abstract][Full Text] [Related]
36. Biological drug and drug delivery-mediated immunotherapy.
Xiao Q; Li X; Li Y; Wu Z; Xu C; Chen Z; He W
Acta Pharm Sin B; 2021 Apr; 11(4):941-960. PubMed ID: 33996408
[TBL] [Abstract][Full Text] [Related]
37. Application of PD-1 Blockade in Cancer Immunotherapy.
Wu X; Gu Z; Chen Y; Chen B; Chen W; Weng L; Liu X
Comput Struct Biotechnol J; 2019; 17():661-674. PubMed ID: 31205619
[TBL] [Abstract][Full Text] [Related]
38. New checkpoints in cancer immunotherapy.
Ni L; Dong C
Immunol Rev; 2017 Mar; 276(1):52-65. PubMed ID: 28258699
[TBL] [Abstract][Full Text] [Related]
39. Endocrine Toxicity of Cancer Immunotherapy Targeting Immune Checkpoints.
Chang LS; Barroso-Sousa R; Tolaney SM; Hodi FS; Kaiser UB; Min L
Endocr Rev; 2019 Feb; 40(1):17-65. PubMed ID: 30184160
[TBL] [Abstract][Full Text] [Related]
40. Resistance to Checkpoint Inhibition in Cancer Immunotherapy.
Barrueto L; Caminero F; Cash L; Makris C; Lamichhane P; Deshmukh RR
Transl Oncol; 2020 Mar; 13(3):100738. PubMed ID: 32114384
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
